Processing...
Clinical Trials for Melanoma
Search
Search
There are 161 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
161 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with metastatic/unresectable melanoma (PD‑1–refractory or PD‑1–naïve) or metastatic clear‑cell RCC refractory to PD‑1/PD‑L1–based therapy receive pembrolizumab (PD‑1 blockade) combined with high‑dose aldesleukin/IL‑2 (T‑cell activation) given inpatient. Single‑arm design aims to improve objective response; excludes significant autoimmune disease, prior severe irAEs, active infection, or major cardiopulmonary compromise.
ClinicalTrials.gov ID: NCT05155033
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–1), including those with small stable brain mets, receive nonmyeloablative lymphodepletion (cyclophosphamide/fludarabine) followed by a single infusion of autologous tumor-infiltrating lymphocytes and high‑dose IL‑2; TILs are expanded from a resected metastasis and act via tumor‑reactive T‑cell–mediated killing augmented by IL‑2. Key exclusions include active infection, significant autoimmune disease, uncontrolled cardiopulmonary disease, HIV/hepatitis, and systemic steroids.
ClinicalTrials.gov ID: NCT03467516
TrialFetch AI summary: Adults with inoperable stage III/IV melanoma that has progressed after prior anti–PD-1 therapy (with prior BRAF-targeted therapy if BRAF V600+) receive high-dose bolus IL-2 (IL-2 receptor agonist) plus low-dose ipilimumab (anti–CTLA-4) followed sequentially by nivolumab (anti–PD-1), with up to three repeatable courses. Excludes active brain metastases and requires ECOG 0–1 and adequate cardiac/pulmonary function given HD IL-2 toxicity.
ClinicalTrials.gov ID: NCT04562129
TrialFetch AI summary: Pediatric trial of pembrolizumab (anti–PD-1 monoclonal antibody) monotherapy for children/adolescents with advanced melanoma (currently enrolling ages ≥12–≤18) and biomarker-selected solid tumors (MSI-H or TMB ≥10 mut/Mb), plus a cohort for relapsed/refractory classic Hodgkin lymphoma (ages 3–<18) and an adjuvant cohort for resected high-risk melanoma (ages 12–<18). Key exclusions include prior PD-1/PD-L1/CTLA-4 therapy and active CNS metastases or autoimmune disease; dosing is IV q3 weeks (2 mg/kg, max 200 mg).
ClinicalTrials.gov ID: NCT02332668
TrialFetch AI summary: Adults with HLA-A2–positive, tyrosinase-expressing metastatic melanoma (ECOG 0–1), including those progressed after checkpoint inhibitors and, if BRAF V600–mutant, after BRAF/MEK therapy, receive a single infusion of autologous T cells retrovirally engineered to express the 1383I TCR targeting tyrosinase/HLA-A2. Dose-escalation assesses safety/MTD and early activity signals; key exclusions include active/uncontrolled brain metastases, systemic steroids, significant organ dysfunction, and prior tyrosinase-directed immunotherapy.
ClinicalTrials.gov ID: NCT02870244
TrialFetch AI summary: Enrolls adults with unresectable/metastatic melanoma progressing after PD‑1/PD‑L1 therapy and other checkpoint inhibitor–responsive solid tumors for AB821 monotherapy, an IV CD8‑IL21 fusion immunotherapy that selectively activates IL‑21 signaling in CD8+ T cells to enhance cytotoxicity and T‑cell memory. Patients must have ECOG 0–1 and adequate organ function; key exclusions include active autoimmune disease requiring treatment, untreated/unstable CNS metastases, significant cardiovascular disease, chronic immunosuppression, and prior IL‑21–based therapy.
ClinicalTrials.gov ID: NCT07027488
TrialFetch AI summary: Enrolling adults (and ≥12 in one cohort) with unresectable stage III/IV melanoma that has progressed after anti–PD-1/PD-L1 therapy (and after BRAF±MEK for V600-mutant), excluding ocular or active CNS disease and >2 prior systemic lines. Intratumoral KB707, an oncolytic HSV-1 engineered to express IL-12 and IL-2, is given with checkpoint blockade (Opdualag or pembrolizumab) to enhance local/systemic antitumor immunity.
ClinicalTrials.gov ID: NCT05970497
TrialFetch AI summary: Adults with advanced solid tumors driven by MAPK pathway alterations, including cohorts for NRAS‑mutant melanoma, BRAF‑altered melanoma/other tumors, KRAS/NRAS‑mutant non‑melanoma cancers, and BRAF‑altered glioma, receive once‑daily oral NST‑628. NST‑628 is an investigational, brain‑penetrant pan‑RAF/MEK molecular glue that stabilizes inactive RAF–MEK complexes to block MEK/ERK signaling; prior BRAF/MEK inhibitor exposure is excluded in expansion cohorts.
ClinicalTrials.gov ID: NCT06326411
TrialFetch AI summary: Adults with unresectable stage III/IV melanoma (ECOG 0–1), including PD‑1–naïve, previously treated, or PD‑1–refractory cohorts, receive nivolumab plus hydroxychloroquine (an autophagy/lysosomal inhibitor) or nivolumab/ipilimumab plus hydroxychloroquine. Aims include defining HCQ dose with PD‑1/CTLA‑4 blockade and assessing response to nivolumab+HCQ, with key exclusions for active severe autoimmune disease, unstable CNS disease, and significant comorbidities.
ClinicalTrials.gov ID: NCT04464759